Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Circulating Tumor Cell
- Lung Cancer
- Surgery
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
A multicenter single arm phase II trial. 40 patients with pathology proven stage I-IIIA NSCLC that are eligible for resection will be enrolled in this study. All patients will receive one dose of cetuximab prior to surgery. Blood will be drawn on multiple timepoints to assess te amount of circulatin...
A multicenter single arm phase II trial. 40 patients with pathology proven stage I-IIIA NSCLC that are eligible for resection will be enrolled in this study. All patients will receive one dose of cetuximab prior to surgery. Blood will be drawn on multiple timepoints to assess te amount of circulating tumor cells
Tracking Information
- NCT #
- NCT04648189
- Collaborators
- Dutch Cancer Society
- Investigators
- Principal Investigator: Egbert Smit, prof The Netherlands Cancer Institute-Antoni van Leeuwenhoek Principal Investigator: Marjolein van Egmond, prof Amsterdam UMC
Get Well Soon